UBS Starts Oruka Therapeutics (ORKA) at Buy

UBS analyst Michael Yee initiates coverage on Oruka Therapeutics (NASDAQ: ORKA) with a Buy rating and a price target of $50.00.

The analyst comments: "OLMA is the only SMID-biotech with a late-stage Phase III SERD in both 1L and 2L metastatic setting. We believe the company still holds significant upside/downside potential even after the recent November move higher with four major catalysts coming in 2026. We see both OLMA’s palazestrant SERD and also new KAT6 breast cancer drug playing important roles in the stock this year with key readouts from both in 2026."

For an analyst ratings summary and ratings history on Oruka Therapeutics click here. For more ratings news on Oruka Therapeutics click here.

Shares of Oruka Therapeutics closed at $26.62 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters
• Aurora Spine settles patent dispute, secures $600K insider loan